Since joining Fitzpatrick in 1989 Ray has concentrated in the areas of patent counseling, contentious proceedings before the United States Patent and Trademark Office, application writing, prosecution, litigation, licensing and due diligence primarily involving the chemical, food, pharmaceutical and biotechnological sciences. He chairs the firm’s Biotechnology Practice Group.
Ray has also prepared and provided counsel on numerous chemical, pharmaceutical and food related patent applications and patents for a number of clients and has extensive experience in the prosecution of both U.S. patent applications and international patent applications under the Patent Cooperation Treaty. He has also been substantially involved in various patent litigations, reexaminations, interferences and reissues and was also lead counsel in a number of inter-partes reviews.
Prior to joining Fitzpatrick, Ray worked for nine years as a chemist for the General Foods Corporation. His technological background has been instrumental in facilitating his quick understanding of the technology that is important to his clients.
Ray Mandra led a team of Fitzpatrick attorneys that handled the patent due diligence for Valeant Pharmaceutical's $11 billion dollar acquisition of Salix Pharmaceutical. His strong technical background coupled with over 27 years of experience in both patent prosecution and litigation matters allowed Ray to quickly understand the patent issues associated with the complex technology being acquired and provide the client with the necessary counsel to assist in consummating the purchase.